Search for Potential Neuroprotectors for Correction of Cognitive and Behavioral Disorders After Ketamine Anesthesia Among 2′-R-6’H-Spiro(cycloalkyl-, heterocyclyl)[1,2, 4]triazolo[1,5-C]-Quinazolines: Fragment-Oriented Design, Molecular Docking, ADMET, Synthesis and In Vivo Study
Preprint
- 4 April 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives: Ketamine anesthesia frequently causes postoperative cognitive dysfunction and behavioral disorders, with limited effective therapeutic options. This study explores novel neuroprotective compounds targeting multiple pathways in neurological disorders following ketamine anesthesia through the design, synthesis, and evaluation of 2'-R-6'H-spiro(cycloalkyl-, heterocyclyl)[1,2,4]triazolo[1,5-c]quinazolines. Methods: Using fragment-oriented design, we synthesized 40 spiro-triazoloquinazolines via [5+1]-cyclocondensation. Molecular docking assessed binding affinities to glutamate receptor GluA3, while ADMET analyses evaluated pharmacokinetic properties. Selected compounds were tested in a ketamine-induced cognitive impairment rat model with behavioral assessment via open field test. Neurobiochemical analyses measured inflammatory markers, apoptotic regulators, and gene expression in hippocampal tissue. Results: Molecular docking showed superior binding affinities to GluA3 compared to reference nootropics, while ADMET analyses confirmed favorable drug-likeness profiles. In vivo evaluation demonstrated compounds 25, 26, and 32 effectively normalized ketamine-disrupted behavioral parameters, reducing anxiety and improving cognitive function more effectively than piracetam and fabomotizole. Neurobiochemical analyses revealed compound-specific mechanisms: compound 31 showed potent anti-inflammatory effects (72% reduction in IL-1β, 80% reduction in caspase-1), while compound 26 enhanced cell survival pathways (96% increase in Bcl-2) and hypoxic adaptation (3.5-fold increase in HIF-1 mRNA). Structure-activity relationship analyses established that spiro-junction type and 2'-position substituent critically determine pharmacological profiles. Conclusions: These novel spiro-triazoloquinazolines demonstrate promising neuroprotective properties for treating cognitive and behavioral disorders associated with ketamine anesthesia through multiple mechanisms including anti-inflammatory, anti-apoptotic, and adaptive pathway modulation. Their superior efficacy compared to current treatments positions them as candidates for further development in post-anesthetic cognitive dysfunction and potentially in post-viral and trauma-related neurological conditions.Keywords
All Related Versions
This publication has 66 references indexed in Scilit:
- Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysisClinical Neurology and Neurosurgery, 2024
- Reaction of [2-(3-hetaryl-1,2,4-triazol-5-yl)phenyl]amines with ketones: a density functional theory studyTheoretical Chemistry Accounts, 2024
- Pre-adolescence repeat exposure to sub-anesthetic doses of ketamine induces long-lasting behaviors and cognition impairment in male and female rat adultsIBRO Neuroscience Reports, 2024
- Unauthorized ingredients in “nootropic” dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agentsDrug Testing and Analysis, 2023
- Association between intraoperative ketamine and the incidence of emergence delirium in laparoscopic surgeries: an observational studyBrazilian Journal of Anesthesiology (English Edition), 2022
- Ketamine: A Paradigm Shift for Depression Research and TreatmentNeuron, 2019
- The 5-HT2A serotonin receptor in executive function: Implications for neuropsychiatric and neurodegenerative diseasesNeuroscience & Biobehavioral Reviews, 2016
- The use of spirocyclic scaffolds in drug discoveryBioorganic & Medicinal Chemistry Letters, 2014
- Anesthesia and Apoptosis in the Developing Brain: An UpdateCurrent Anesthesiology Reports, 2012
- Systemic inflammation enhances surgery-induced cognitive dysfunction in miceNeuroscience Letters, 2011